Kenai Therapeutics has dosed the first patient in its multi-centre Phase I REPLACE trial evaluating the allogeneic neuron ...

Kenai Therapeutics, a clinical-stage biotechnology company pioneering next generation approaches to cure neurological conditions, today announced that the first patient has been dosed in its Phase 1 ...

Cancer Research UK's Centre for Drug Development is sponsoring and conducting the phase I/II clinical trial of ALETA-001, the lead agent in Aleta Biotherapeutics' portfolio. Additional clinical trial ...

ADI-001 demonstrated 75% overall response rate (ORR) and 69% complete response (CR) across all dose levels with favorable safety and tolerability profile in patients with relapsed/refractory ...

Cynata Therapeutics completes patient enrolment in phase 2 trial of CYP-001 in adults with newly diagnosed, high risk aGvHD: Melbourne, Australia Tuesday, December 16, 2025, 14:00 ...

HT-001 demonstrated significant efficacy in reducing skin toxicities from EGFR inhibitors, achieving primary endpoints in all patients. Patients experienced improved quality of life, with 66% ...

IGV-001, an investigational autologous cell immunotherapeutic combination product, may offer clinically meaningful overall ...

PHILADELPHIA--(BUSINESS WIRE)--Seneca Therapeutics, Inc. (“STI”), a clinical-stage biopharmaceutical company dedicated to the development of targeted oncolytic immunotherapeutics for cancer based on ...

BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing next-generation therapeutics, ...

IGV-001 improved survival for newly diagnosed glioblastoma in a phase 2b trial, with patients living a median 20.3 months and no serious safety issues.

Azura Ophthalmics announced it has received positive feedback from a pre-New Drug Application (NDA) meeting with the US Food ...